DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Selara (Drug)

Phase: N/A

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

To collect the efficacy and safety information of Eplerenone on patients with hypertension related to their appropriate use in daily practice.

Clinical Details

Official title: Eplerenone Observational Study Of Safety And Efficacy Evaluation To Normalize Blood Pressure For Clinical Effectiveness

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome:

Number of Participants With Treatment Related Adverse Events.

Number of Participants With Serious Treatment Related Adverse Events.

Secondary outcome:

Change in Systolic Blood Pressure Over Time.

Change in Diastolic Blood Pressure Over Time.

Number of Participants That Responded to Selara Treatment.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or Female patients who are prescribed Selara tablet for Hypertension.

Exclusion Criteria:

- Subjects who have been prescribed Selara tablet.

Locations and Contacts

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: June 2008
Last updated: November 20, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017